Unique technology, Unique market
Xspray Pharma’s unique technology could improve the quality of life, and make it possible for more patients to access improved Protein Kinase Inhibitor (PKI) drugs for treatment of cancer.
-
Latest report
Interim Report Q2 2023 -
Subscribe
Get our latest press releases and reports

Press releases
Press release 2023-09-15
Xspray Pharma appoints Chief Commercial Officer to drive upcoming Dasynoc™ US product commercialization
Regulatory press release 2023-09-11
Xspray Pharma and Bristol Myers Squibb Reach Settlement on Dasynoc™ Patent Litigation, Paving Way for Early Market Launch
Regulatory press release 2023-08-02
Interim Report Second Quarter 2023
Regulatory press release 2023-07-31
New number of shares and votes in Xspray Pharma
Regulatory press release 2023-07-11
Xspray Pharma receives request for additional information concerning Dasynoc from FDA

Xspray Pharma uses its innovative, patented technology to develop amorphous product candidates that are improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. Often the original companies have secondary patents that are based on the crystalline forms of the active substance. Since Xspray Pharma’s products are amorphous, they can be marketed as soon as the original companies’ drug substance patents expire. This is a unique opportunity for a favorable market establishment on a multi billion dollar market.

We see a large potential for our product portfolio. Our technology is compatible for most of the more than 80 US markeded protein kinase inhibitors. The company’s new porduct candidates are being developed in the same manner as the company´s initial product, XS004 dasatinib. The process is reproducible and reduces the effective developing time for future products in our pipeline. This is an exciting time! Per Andersson, CEO